Controlled Lethality.
Same force. Reduced mortality. The first projectile engineered to contain wound-cavity hemorrhage without compromising ballistic performance.
Law enforcement exists in a binary: lethal force or non-lethal force. Nothing exists in between. The tools that stop a threat also maximize hemorrhage — and the legal exposure that follows.
No existing ammunition manufacturer has a product or incentive to reduce those payouts. They profit from the status quo. Lazarus fills this gap.
LZR-C is not less-lethal. It is not non-lethal. It is deadly force — engineered with controlled outcomes.
Lazarus gives officers something they have never had before — the ability to act decisively in a threat situation while maximizing the chance that the person they shot survives to face justice. That changes everything about how communities and departments relate to use-of-force incidents.— Alex Brown, COO & Former Military Police
The LZR-C Projectile
A patented copper-jacketed projectile with an internal cavity containing a biocompatible hemostatic compound. Mechanically released on terminal impact. Full FBI protocol ballistic parity.
FBI protocol verified: 12–18" gelatin penetration, controlled expansion, and weight retention. Identical stopping power to standard law enforcement duty ammunition. No operational compromise.
Biocompatible compound mechanically released on terminal impact. Distributes into wound channel. Reduces hemorrhage cascade. Not a medical device — a mechanical ballistics enhancement.
Continuation-in-part patent covers the release mechanism, hemostatic loading methodology, and core concept. Broad IP estate. PCT filing in Phase 1 roadmap.
| Caliber | 9mm Luger |
| Penetration | 12–18 inches (FBI Protocol) |
| Expansion | Benchmarked against Speer Gold Dot |
| Hemostatic Agent | Proprietary — FDA-cleared compound class |
| ATF Classification | Conventional ammunition |
| IP Status | PCT patent filing in progress |
| Wound Window Extension | Up to 50% (projected, pending animal study) |
| Validation Status | Ballistics gel testing complete. Animal study scheduled. |
The Right Team
for This Problem
Chemical engineering background. Three years at Deloitte in M&A. Rice MBA. Originated the LZR-C patent in 2016 in response to the Dallas police shooting. Drives IP portfolio, partnerships, and licensing strategy.
Texas A&M machinist. 10+ years manufacturing experience. Built every prototype. Conducted 500+ ballistic tests. The mechanical and manufacturing brain behind LZR-C's physical reality.
Former Marine Corps military police officer. Ran the law enforcement academy. 4.5 years teaching continuum of force, case law, and legal obligations. First-hand operational experience with gunshot outcomes and deep law enforcement networks.
Counsel from the Highest Levels of the Field
John brings decades of special operations experience and a deep understanding of weapons systems, wound ballistics, and the tactical realities of lethal force. His operational perspective shapes both the product design and the training protocols Lazarus recommends to agency partners.
Dr. Batchinsky is a leading researcher in battlefield trauma and hemostasis at the Geneva Foundation. His scientific guidance ensures Lazarus’s clinical claims are grounded in peer-reviewed evidence and that the animal study design will produce data that stands up to the most rigorous independent scrutiny.
A New Category in
Law Enforcement Ammunition
We are a ballistics technology and brand company. We do not manufacture ammunition — we develop and license the LZR-C projectile to existing manufacturers who load and distribute it. Lower capital intensity. Higher IP leverage.
LZR-C functions as an ingredient brand. Winchester, Hornady, or Remington loads LZR-C; municipalities mandate procurement; "LZR-C Equipped" appears on every box. Brand equity compounds independently of manufacturer relationships.
Built with Law Enforcement.
For the Communities They Serve.
Congressional support is not a secondary priority — it is a core commercial strategy. Bipartisan backing from legislators transforms a commercial product into a political mandate.
Who It's Built For
- Pre-assembled projectiles — easy integration into existing lines
- New demand channel from municipalities and procurement mandates
- "LZR-C Equipped" co-branding on packaging
- No cannibalization of existing products — a new category
- Manufacturer as distribution partner, not IP owner
- No performance compromise — same stopping power as standard duty ammo
- Designed by operators, for operators (Alex Brown, USMC MP)
- Not "less lethal" — this is deadly force with controlled outcomes
- Legally defensible documentation of wound-mitigation intent
- Data-backed use-of-force standard via WBAF testing
- Reduce $2M+ per-settlement liability exposure
- Insurance premium reduction for LZR-C adopting agencies
- Political accountability tool for city councils
- Data-backed procurement standard via WBAF
- Demonstrates institutional commitment to responsible force
Proof of Progress
Ben Omonira originates the LZR-C concept following the Dallas police shooting. Continuation-in-part patent filed covering release mechanism and hemostatic loading.
Early-stage engagement with Bryan Police Department. First institutional validation of market interest.
Nathan Panak has conducted over 500 ballistic tests. Gel testing confirmed hemostatic compound distributes into wound channel on terminal impact.
Active conversations with Vista Outdoors and Axon Enterprise (Taser) on potential partnership and integration.
IACUC protocol developed. Animal study team assembled and ready to execute.
Selected as semi-finalist in the Rice University Venture & Business Building competition — institutional academic validation.
Three-phase roadmap: prototyping + PCT filing → NIJ testing + AI simulation → animal study + IP reinforcement.
The Standard for Responsible Force
“Nothing is more important than saving lives. That is the only reason this company exists.”Ben Omonira, CEO & Co-Founder
Get In Touch.
Seven months. Three phases. One milestone: independent validation of LZR-C efficacy that unlocks institutional adoption and partnership conversations.
Message Sent
Thank you for reaching out. We will respond personally within 48 hours.